Is there a role for reduced-intensity haematopoietic stem cell transplantation for indolent non-Hodgkin's lymphoma?
The therapeutic options for the indolent non-Hodgkin's lymphomas have evolved significantly over the years. However, at present, allogeneic haematopoietic stem cell transplantation (HSCT), despite its significant transplant associated complications, is still the only option which may be delivered with curative potential. The debut of reduced-intensity conditioning regimens has extended the applicability of allogeneic transplants to groups of patients ineligible for conventional myeloablative allografts. However, there are still substantial hurdles to overcome, namely that of relapse, graft-versus-host disease and infection. Whilst follow-up is still relatively limited for a disease group with a median survival of up to 10 years, early results are extremely encouraging and further studies are warranted.
Ho
Aloysius Y L
AY
Department of Haematological Medicine, King's College Hospital, Denmark Hill, London, UK. aloysius.ho@kcl.ac.uk
Pagliuca
Antonio
A
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006086:Graft vs Host Disease / Q000517:prevention & control; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000150:complications / Q000628:therapy*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D000970:Antineoplastic Agents